Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Assets (2016 - 2025)

Historic Assets for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $122.0 million.

  • Aytu Biopharma's Assets rose 496.7% to $122.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $122.0 million, marking a year-over-year increase of 496.7%. This contributed to the annual value of $124.2 million for FY2025, which is 515.01% up from last year.
  • As of Q4 2025, Aytu Biopharma's Assets stood at $122.0 million, which was up 496.7% from $125.0 million recorded in Q3 2025.
  • Aytu Biopharma's Assets' 5-year high stood at $271.6 million during Q1 2021, with a 5-year trough of $115.8 million in Q3 2024.
  • Its 5-year average for Assets is $155.4 million, with a median of $134.7 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 7330.73% in 2021, then tumbled by 4819.74% in 2022.
  • Aytu Biopharma's Assets (Quarter) stood at $223.8 million in 2021, then crashed by 36.81% to $141.4 million in 2022, then dropped by 7.2% to $131.2 million in 2023, then fell by 11.45% to $116.2 million in 2024, then grew by 4.97% to $122.0 million in 2025.
  • Its Assets stands at $122.0 million for Q4 2025, versus $125.0 million for Q3 2025 and $124.2 million for Q2 2025.